The GO biological process and KEGG signalling pathway enrichment analysis for these targets predicted that DHLP could regulate MAPK1, STAT3, AKT1, MAPK8, TNF, and other targets and that DHLP could regulate TNF, toll-like receptor, HIF-1, and other signalling pathways as well as osteoclast differentiation to suppress inflammation and to regulate immune function to treat RA. This evidence concerns the gene STAT3 and rheumatoid arthritis.